More recently, FLT PET-CT assessment to novel targeted therapy with a c-MET inhibitor and MDM2 inhibitor in lung cancer revealed an early response at two selected time points, namely 9 days in one participant and at 4 weeks in two other participants.26 This evidence concerns the gene MDM2 and lung carcinoma.